PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
42.75
+0.35 (+0.83%)
At close: 4:02PM EDT

42.75 0.00 (0.00%)
After hours: 7:58PM EDT

Stock chart is not supported by your current browser
Previous Close42.40
Open42.27
Bid42.75 x 2900
Ask42.75 x 1000
Day's Range42.24 - 42.77
52 Week Range37.12 - 46.47
Volume19,052,053
Avg. Volume23,252,524
Market Cap237.687B
Beta (3Y Monthly)0.43
PE Ratio (TTM)21.96
EPS (TTM)1.95
Earnings DateJul 30, 2019
Forward Dividend & Yield1.44 (3.40%)
Ex-Dividend Date2019-08-01
1y Target Est45.75
Trade prices are not sourced from all markets
  • Dow Jones Today: China, Earnings Anticipation Stall Stocks on Monday
    InvestorPlace7 hours ago

    Dow Jones Today: China, Earnings Anticipation Stall Stocks on Monday

    A somewhat slack economic report out of China, the world's second-largest economy, stood in the way of stocks notching big gains Monday.Source: Shutterstock China said its second-quarter GDP rose "just" 6.2%, below economists' forecasts calling for 6.3% and good for the country's slowest pace of economic growth in 27 years. Chinese economists are now expecting 2019 growth of 6%, well below the original forecast of 6.5%.Here in the U.S., the Nasdaq Composite rose 0.17% while the S&P 500 added just 0.02%, and the Dow Jones Industrial Average added 0.10%. That after the major domestic benchmarks touched record highs early in Monday's session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCitigroup (NYSE:C) got second-quarter earnings season rolling today, reporting that net income rose to $4.8 billion, or $1.95 per share, from $4.5 billion, or $1.63 per share, a year earlier. Analysts expected per share earnings of $1.80. * 7 Dependable Dividend Stocks to Buy Citi is not a member of the Dow Jones Industrial Average, but the bank's positive earnings surprise could be a sign of things to come. That would be a good thing with Dow components JPMorgan Chase (NYSE:JPM) and Goldman Sachs (NYSE:GS) stepping into the earnings confessional on Tuesday. A Tasty WinnerMcDonald's (NYSE:MCD) posted a modest gain today, but that was enough to extend its year-to-date returns to around 22%, solidifying the burger joint as one of 2019's best-performing members of the Dow. In a note out Monday, Tesley Group reiterated an "outperform" rating on McDonald's while boosting its price target on the stock to $230 from $210. That implies decent upside as Monday closed just above $214.McDonald's shares "offer both offensive and defensive investment attributes for both good times and slower times, and with its menu of both premium and value-priced options," according to Tesley.Piper Jaffray and Wells Fargo also boosted price targets on McDonald's to $226 and $235, respectively. Options ActionMicrosoft (NASDAQ:MSFT), the largest U.S. company by market value, reports earnings on Thursday. It is expected to be a bellwether report given the stock's sheer heft in broad market benchmarks and technology sector funds.Microsoft remains around the vaunted $1 trillion market cap. It appears some options traders are betting on good news from Microsoft's earnings report. At one point on Monday, calls were outpacing puts in the name by a margin of more than 2-to-1, according to Schaeffer's Investment Research. Historically, shares of Microsoft move nearly 3% following the company's earnings reports. Pharma and Politics … AgainThough in modest fashion, the Dow's pharmaceuticals components - Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) - each closed higher today despite drug price commentary from former Vice President Joe Biden, a 2020 Democratic frontrunner.Biden "unveiled a healthcare plan on Monday estimated to cost $750 billion and paid for partly by higher tax rates for the wealthy and doubled tax rates on capital gains," according to Reuters.This is not a "Medicare For All" gambit. Rather, Biden's healthcare proposal is seen as a refresher of Obamacare, which was implemented when he was vice president. Bottom Line for Dow Jones StocksIt's earnings season, meaning it's also complaining season for U.S. companies. Expect one of the primary complaints to be about the strength of the dollar."Of the 5% of S&P 500 companies that have reported so far, more than half of them cited a strong greenback as a headwind to their business in the second quarter, according to FactSet, which parsed through companies' conference call transcripts to look for specific factors weighing on company earnings," reports CNBC.With the Invesco DB US Dollar Index Bullish Fund (NYSEARCA:UUP) up nearly 3% year-to-date, dollar-related earnings commentary gets us back to a familiar theme: the impetus for the Federal Reserve to lower interest rates and do so soon.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential The post Dow Jones Today: China, Earnings Anticipation Stall Stocks on Monday appeared first on InvestorPlace.

  • Reuters18 hours ago

    Biden healthcare plan would curb drug prices, raise taxes on rich

    Former U.S. Vice President Joe Biden, the front-runner in the Democratic presidential race, unveiled a healthcare plan on Monday estimated to cost $750 billion and paid for partly by higher tax rates for the wealthy and doubled tax rates on capital gains. "The Biden plan to protect and build on the Affordable Care Act" seeks to strengthen the signature healthcare plan, popularly known as Obamacare, enacted under former Democratic President Barack Obama. Biden was Obama's vice president for eight years.

  • Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
    Zacks4 days ago

    Drug Pricing Woes Linger on Repealing Drug Rebate Proposal

    Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.

  • AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
    Zacks4 days ago

    AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC

    The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.

  • Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump
    Yahoo Finance4 days ago

    Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump

    Ruud Dobber, AstraZeneca’s biopharmaceuticals president, weighs in on the Trump administration walking back one change it had been seeking in the drug space.

  • SNY or PFE: Which Is the Better Value Stock Right Now?
    Zacks4 days ago

    SNY or PFE: Which Is the Better Value Stock Right Now?

    SNY vs. PFE: Which Stock Is the Better Value Option?

  • Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
    Zacks4 days ago

    Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

    Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

  • Reuters5 days ago

    US STOCKS-S&P 500, Dow climb as health insurers, financials gain

    The Dow and S&P 500 rose on Thursday to close at record highs as health insurers gained after the Trump administration scrapped a plan designed to rein in prescription drug prices, while financial shares climbed with bond yields. A 5.5% gain in UnitedHealth Group Inc helped the Dow close above 27,000 points for the first time.

  • Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
    Yahoo Finance5 days ago

    Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates

    The drug companies provide rebates to PBMs in exchange for distributing their products.

  • 4 Drug Stocks Getting Smashed
    InvestorPlace5 days ago

    4 Drug Stocks Getting Smashed

    U.S. equities were hitting new record highs, with the Dow Jones Industrial Average topping 27,000 for the first time ever while the S&P 500 hits 3,000. The catalyst is an all too familiar one: The promise of more cheap money from the Federal Reserve, with chairman Jerome Powell strongly signaling a rate cut later this month in response to uneven economic data.But the gains are being trimmed in mid-day trading after a strong inflation report suggests the U.S.-China trade spat is starting to have an impact on import prices. And higher inflation would undermine the Fed's desire to lower rates. Stocks, obviously, wouldn't react well to that. * 10 Stocks to Sell for an Economic Slowdown A number of big drug stocks are getting hit amid the pullback on reports the Trump Administration has pulled its plan to eliminate rebates from government drug plans. Had this rule gone through, drug stocks would've been relatively unaffected. Investors now fear the administrations next move to try to lower drug prices. Here are four drug stocks to sell on the news:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (PFE) Click to EnlargePfizer (NYSE:PFE) shares are dropping hard out of a four-month uptrend threatening to cut below both its 50-day and 200-day moving averages. This comes after the stock bonked on resistance from its December high and remains mired in a sideways range that has been in play since last summer.The company will next report results on July 30 before the bell. Analysts are looking for earnings of 75 cents per share on revenues of $13.4 billion. When the company last reported on April 30, earnings of 85 cents per share beat estimates by 10 cents on a 1.6% rise in revenues. Eli Lilly (LLY) Click to EnlargeShares of Eli Lilly (NYSE:LLY) are falling down and out of a four month consolidation range, returning to levels not seen since December. This caps a decline of more than 15% from the highs hit in late March. With the 50-day and 200-day moving averages already lost, watch for a drop down to mid-2018 support near $105, which would be worth a loss of another 4% from here. * 3 Forgotten Tech Stocks Worth Remembering The company will next report results on July 30 before the bell. Analysts are looking for earnings of $1.45 per share on revenues of $5.6 billion. When the company last reported on April 30, earnings of $1.33 per share matched expectations on a 2.6% rise in revenues. Merck (MRK) Click to EnlargeMerck (NYSE:MRK) shares are dropping hard and fast away from the two-month consolation range that capped a nice 20% rally off of its 200-day moving average. The stock has gained more than 50% from the lows seen in early 2018 and a ripe for a significant profit taking pullback -- likely resulting in a revisiting of the April lows.The company will next report results on July 30 before the bell. Analysts are looking for earnings of $1.16 per share on revenues of $10.9 billion. When the company last reported on April 30, earnings of $1.22 per share beat estimates by 17 cents on a 7.8% rise in revenues. Bristol-Myers Squibb (BMY) Click to EnlargeShares of Bristol-Myers Squibb (NYSE:BMY) have returned to lows near $44 that have been tested multiple times in a pattern going back to early 2017. The range is rather wide, with prices down more than a third from the highs hit in February 2018. The company is continuing to work with regulators to waylay concerns over its proposed acquisition of Celgene (NASDAQ:CELG). * 10 Best ETFs for 2019: The Race for 1 Intensifies The company will next report results on July 25 before the bell. Analysts are looking for earnings of $1.06 per share on revenues of $6.1 billion. When the company last reported on April 25, earnings of $1.10 beat estimates by two cents on a 14% rise in revenues.As of this writing, William Roth held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell for an Economic Slowdown * 7 Marijuana Penny Stocks That I May Buy * 7 of The Best Schwab ETFs for Low Fees The post 4 Drug Stocks Getting Smashed appeared first on InvestorPlace.

  • Barrons.com5 days ago

    Drug Stocks Are Falling Because Trump’s Next Move on Pricing Could Be Trouble

    Investors are worried that the Trump administration’s war to rein in drug prices is just heating up—and that big pharma could be the next target.

  • Here's Why CVS Health Stock Is On the Move Today
    Motley Fool5 days ago

    Here's Why CVS Health Stock Is On the Move Today

    A White House proposal that could have lowered drug prices has gone belly up.

  • Here's Why Sangamo Therapeutics Jumped 23% in June
    Motley Fool5 days ago

    Here's Why Sangamo Therapeutics Jumped 23% in June

    The biotech's gene therapy to treat hemophilia A looks promising.

  • Reuters5 days ago

    UPDATE 2-Walgreens expands epinephrine shot partnership as shortage persists

    Walgreens Boots Alliance Inc said on Thursday it expanded its partnership with Kaleo Inc to include the company's epinephrine auto-injectors for infants and toddlers in its pharmacies amid a national shortage of the emergency allergy shots. Walgreens already offers two other doses of Kaleo's emergency allergy shots, Auvi-Q, under a partnership that the drugstore chain entered with the company in September last year.

  • Pfizer Stock Is The Biggest Pharma — But Should You Buy It?
    Investor's Business Daily5 days ago

    Pfizer Stock Is The Biggest Pharma — But Should You Buy It?

    Pfizer stock has run sideways this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?

  • Investing.com5 days ago

    Pfizer Falls 3%

    Investing.com - Pfizer (NYSE:PFE) fell by 3.13% to trade at $42.66 by 10:18 (14:18 GMT) on Thursday on the NYSE exchange.

  • Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
    Zacks5 days ago

    Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)

    Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.

  • GuruFocus.com6 days ago

    US Indexes Close Higher After Dovish Fed Reports

    S&P; 500 closes at 2,993.07 for a gain of 0.45%

  • Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill
    Zacks6 days ago

    Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill

    Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.

  • The 10 Biggest Healthcare Stocks
    Motley Fool6 days ago

    The 10 Biggest Healthcare Stocks

    How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

  • Companies to Watch: T-Mobile joins S&P 500, Tesla to ramp up production, Marriott faces lawsuit
    Yahoo Finance6 days ago

    Companies to Watch: T-Mobile joins S&P 500, Tesla to ramp up production, Marriott faces lawsuit

    T-Mobile, Tesla, Marriott, GlaxoSmithKline, Pfizer and Caliva are the companies to watch.

  • Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
    Zacks6 days ago

    Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA

    FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications

  • Here's Why Array BioPharma Soared 75.4% in June
    Motley Fool6 days ago

    Here's Why Array BioPharma Soared 75.4% in June

    It looks like Novartis let a big one get away.

  • Aerie Completes Enrollment Under Rhopressa Study in Japan
    Zacks7 days ago

    Aerie Completes Enrollment Under Rhopressa Study in Japan

    Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

  • Health Care stocks help lead Wall Street rally
    Yahoo Finance Video4 days ago

    Health Care stocks help lead Wall Street rally

    Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani break down what's driving the health care sector higher.